ADENOVIRAL MEDIATED ISLET GENE TRANSFER
ADENOVIRAL MEDIATED ISLET GENE TRANSFER
批准号:
2763528
负责人:
Kenneth Lewis Brayman
金额:
$6.79万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-30 至 2000-09-29
关键词:
Adenoviridae SCID mouse calbindin diabetes mellitus therapy drug related diabetes mellitus enzyme activity gene therapy glucokinase glucose tolerance test glucose transporter human tissue nonhuman therapy evaluation pancreatic islet function pancreatic islet transplantation tissue /cell culture transfection /expression vector xenotransplantation
中文摘要
糖尿病是一种常见的疾病,估计发生在5%
美国人口的一半。 糖尿病是一个主要的原因
血管疾病导致的过早死亡和失明的主要原因
在工作年龄的成年人中,非创伤性下肢截肢,
肾衰竭需要透析和移植 约10-15
美国医疗保健总预算的10%用于糖尿病。
因此,糖尿病对个人和家庭来说都是一个严重的负担。
社会 糖尿病(I型和II型)发病机制的研究
这表明β细胞功能受损是导致
缺陷。 虽然这两种疾病的发病机制是
不同的是,这两种糖尿病的潜在代谢原因是
胰腺β细胞不能提供足够的胰岛素
足以满足身体的需要,导致高血糖。
血糖控制不当直接导致
特异性和非特异性并发症的发展
糖尿病状态β细胞功能障碍存在于所有糖尿病患者中。
患者 胰岛同种异体移植物也可能表现出β细胞功能障碍。 在
葡萄糖调节的β细胞功能、葡萄糖摄取和代谢是
在发送信息的强制性步骤,导致增加
细胞内Ca 2+,导致胰岛素的生物合成和分泌。这些
葡萄糖转运蛋白是两种蛋白质的直接调节过程
和葡糖激酶。 有人提出GLUT 2和葡萄糖激酶可能
作为葡萄糖传感装置的主要元件串联起作用。
通过在胰岛和β细胞中过表达这些基因,
线,胰岛素释放的显着增加已被证明
葡萄糖诱导的反应。 然而,这一现象并没有被
研究使用人类胰岛。 在本提案中,我们将
将这些候选基因转移到人胰岛组织中,
血管递送腺病毒载体,并检查是否特异性
基因转移将在体外和体内改善胰岛β细胞功能,
vivo. 具体而言,我们将进一步确定适当的条件,
实现高效(大于90%)的基因转移,
经血管输送病毒的人胰岛组织
(动脉灌注)在胰岛移植前灌注整个胰腺
隔离 然后我们将评估病毒感染对代谢的影响
和基因转移(第一、第二、第三代腺病毒载体编码
LacZ报告基因或其他特异性治疗基因在
胰岛组织的功能完整性。最后,我们将研究
腺病毒介导的基因转移到胰岛的有效性
关于纠正β细胞功能障碍以治疗I型糖尿病
和II型糖尿病通过转移GLUT 2和葡萄糖激酶的基因,
人体胰岛组织
英文摘要
Diabetes mellitus is a common disorder, estimated to occur in 5 percent
of the population of the United States. Diabetes is a major cause of
premature death from vascular disease and the leading cause of blindness
in working-age adults, of nontraumatic lower extremity amputations, and
of renal failure requiring dialysis and transplantation. About 10-15
percent of the total health care budget in the US is spent on diabetes.
Thus, diabetes represents a serious burden to the individual and to
society. Studies on the pathogenesis of diabetes (both type I and II)
indicate that impaired Beta-cell function accounts for the majority of
the defects. Although the pathogenesis of the two diseases is
different, the underlying metabolic cause of both forms of diabetes is
a failure of the pancreatic Beta cells to provide insulin in an amount
sufficient to meet the body's needs, leading to hyperglycemia.
Improperly controlled hyperglycemia is directly responsible for the
development of the specific and non-specific complications of the
diabetic state. Beta-cell dysfunction is present in all diabetic
patients. Islet allografts may also exhibit Beta-cell dysfunction. In
glucose-regulated Beta-cell function, glucose uptake and metabolism are
obligatory steps in sending the message which results in an increase in
intracellular Ca2+, leading to insulin biosynthesis and secretion. These
processes are directly regulated to two proteins: glucose transporters
and glucokinase. It was proposed that GLUT2 and glucokinase may
function in tandem as primary elements of the glucose sensing apparatus.
By overexpression of these genes in pancreatic islets and Beta-cell
lines, a significant increase of insulin release has been demonstrated
in glucose-induced response. However, this phenomenon has not been
studied using human pancreatic islets. In this proposal, we will
transfer these candidate gene(s) into human pancreatic islet tissue by
vascular delivery of adenoviral vectors and examine whether specific
gene transfer will improve islet Beta-cell function in vitro and in
vivo. Specifically, we will further define appropriate conditions to
achieve highly efficient (greater than 90 percent) gene transfer to
human pancreatic islet tissue by delivering viruses through vascular
(arterial infusion) perfusion of the whole pancreas prior to islet
isolation. We will then assess the metabolic effects of viral infection
and gene transfer (1st, 2nd, 3rd generation adenoviral vectors encoding
LacZ reporter gene or other specific therapeutic gene(s) on the
functional integrity of islet tissue. Finally we will examine the
effectiveness of adenoviral mediated gene transfer to pancreatic islets
on the correction of Beta-cell dysfunction for the treatment of Type I
and II diabetes by transferring the genes for GLUT2 and glucokinase to
human islet tissue.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
-
批准号:8167147
-
项目类别:
-
资助金额:$0.4万
-
财政年份:2010
-
负责人:Kenneth Lewis Brayman
-
依托单位:
CLINICAL TRIAL: UVA ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
-
批准号:8167168
-
项目类别:
-
资助金额:$0.13万
-
财政年份:2010
-
负责人:Kenneth Lewis Brayman
-
依托单位:
CLINICAL TRIAL: UVA ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
-
批准号:7951490
-
项目类别:
-
资助金额:$3.02万
-
财政年份:2009
-
负责人:Kenneth Lewis Brayman
-
依托单位:
CLINICAL TRIAL: ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
-
批准号:7951457
-
项目类别:
-
资助金额:$0.29万
-
财政年份:2009
-
负责人:Kenneth Lewis Brayman
-
依托单位:
CLINICAL TRIAL: ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
-
批准号:7718537
-
项目类别:
-
资助金额:$0.43万
-
财政年份:2008
-
负责人:Kenneth Lewis Brayman
-
依托单位:
CLINICAL TRIAL: UVA ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
-
批准号:7718586
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2008
-
负责人:Kenneth Lewis Brayman
-
依托单位:
ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
-
批准号:7606679
-
项目类别:
-
资助金额:$2.32万
-
财政年份:2007
-
负责人:Kenneth Lewis Brayman
-
依托单位:
ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
-
批准号:7205497
-
项目类别:
-
资助金额:$5.75万
-
财政年份:2005
-
负责人:Kenneth Lewis Brayman
-
依托单位:
ADENOVIRAL MEDIATED ISLET GENE TRANSFER
-
批准号:2906389
-
项目类别:
-
资助金额:$6.77万
-
财政年份:1998
-
负责人:Kenneth Lewis Brayman
-
依托单位:
海外基金